Immuneering Corporation is planning a global pivotal trial in 2026 for atebimetinib in first-line pancreatic cancer after posting successful results of a Phase IIa study of the drug. Immuneering is aiming to position atebimetinib for accelerated approval by the US Food and Drug Administration, but is still hashing out how it will fund and design the trial. Partnering or self-financing options are both on the table.
Key Takeaways
- Immuneering announced positive results for its trial of atebimetinib in first-line pancreatic cancer and plans to launch a pivotal trial in 2026.
The Cambridge, MA-based biotech announced positive results on June 17 of the drug, a MEK inhibitor, combined with gemcitabine/nab-paclitaxel on...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
